Multimodal treatment disparities in pancreatic cancer significantly affect patient survival and care.

• 8,466 patients analyzed; nonmetastatic cases had higher therapy rates than metastatic.
• Non-Hispanic black patients experienced longer delays to treatment compared to non-Hispanic whites.
• Uninsured and Medicaid patients showed the highest odds of not receiving therapy in metastatic cases.

Primary resection strongly predicts improved survival outcomes. Addressing these disparities is critical for enhancing patient care strategies.

Pre-operative shear wave elastography can effectively predict the risk of post-operative pancreatic fistula (POPF) after partial pancreatectomy, impacting surgical decision-making.

• In a study of 305 patients, lower elastography measurements correlated with a higher risk of POPF.
• An integrated prediction model using elastography, BMI, and pancreatic duct dilation accurately assessed POPF risk with AUC values over 0.75.

Utilizing this model could improve patient selection and outcomes in pancreatic surgeries.

Preoperative conversion therapy significantly enhances surgical outcomes for intermediate-stage hepatocellular carcinoma.

• 23.2% of patients in the conversion resection group achieved a complete pathological response.
• Microvascular invasion rates were lower in the conversion group (17.9% vs. 58.6% in direct resection).

Consider conversion therapy to improve pathology and survival before resection in select patients.

• 51.8% of the conversion resection group showed a major pathological response.

Tumor markers may improve patient selection for liver resection in HCC.

• In a study of 803 patients, 32.3% of resectable tumors had high tumor markers (AFP > 500 ng/ml or DCP > 1000 mau/ml).
• TM-high patients had a median survival of 120.7 months, significantly lower than non-TM-high patients at 160.8 months (p = 0.008).

Incorporating tumor markers into resectability criteria could optimize treatment strategies and improve outcomes for patients with HCC.

• TM-high status was an independent predictor for relapse-free survival and overall survival.

A novel risk model using stress granule-related gene signatures (sgrgs) shows promise for improving prognostic accuracy in pancreatic ductal adenocarcinoma (PDAC).

• Four key sgrgs (lama3, itga6, col17a1, top2a) were identified as significant predictors of PDAC prognosis.
• A nomogram combining age, N stage, and risk score demonstrated strong predictive capacity.

Understanding these markers can enhance patient selection for targeted therapies and improve outcomes in PDAC management.

• Immune profiling revealed links to M0 macrophages and CD8 T cells, which may inform treatment strategies.